Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ixazomib + lenalidomide + dexamethasone
- Development stage
- Unknown
- Lead developer
- Takeda
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Ixazomib + lenalidomide + dexamethasone is an oral combination regimen used to treat multiple myeloma, specifically in patients who have received at least one prior therapy. Ixazomib is a proteasome inhibitor that blocks the activity of the 20S proteasome, leading to accumulation of proteins and apoptosis in cancer cells. Lenalidomide is an immunomodulatory agent that interferes with cellular signaling and modulates immune responses, while dexamethasone is a corticosteroid that enhances the anti-myeloma effects of the other agents and has direct cytotoxic activity against myeloma cells. This combination provides a fully oral treatment option for relapsed or refractory multiple myeloma[1][2][3][4][5].
- Brand names
- IRD-lite
- Other names
- ixazomib + lenalidomide + dexamethasone
02
Targets
GR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)CRBN (Cereblon)
Beyond the preview
Go deeper on ixazomib + lenalidomide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ixazomib + lenalidomide + dexamethasone.